Novartis notifies about Phase III COMBI-I study to treat skin cancer

By Nikita Chaurasia  Date: 2020-08-24

Novartis notifies about Phase III COMBI-I study to treat skin cancer

Reportedly, Novartis made an announcement that the COMBI-I study in its third phase that does evaluation of investigational immunotherapy spartalizumab (PDR001), combined with the targeted therapies Mekinist (trametinib) and Tafinlar (dabrafenib) did not produce a primary result of progression-free, investigator-assessed survival.

As per the trusted sources, the trail was conducted on untreated patients with metastatic (Stage IV) BRAF V600 or unresectable (Stage IIIC) mutation-positive cutaneous melanoma, in comparison with Tafinlar + Mekinist treatment alone. Tafinlar and Mekinist are medicines prescribed in combination to treat patients with skin cancer- melanoma.

John Tsai, MD, Chief Medical Officer and Head of Global Drug Development at Novartis states that although the COMBI-I trial did not get to its primary outcome, the report’s analysis offers some important insights of its part like the investigational immunotherapy spartalizumab could possibly contribute to the future cancer therapy combinations. Besides this, it also highlights the significance of Tafinlar + Mekinist for these patients as estimated in the past.

He further added that Novartis is fully dedicated towards curing melanoma patients through ongoing study and they would continue to provide the approved combination therapy Tafinlar + Mekinist to patients across the globe.

He added that they at Novartis extend gratitude to the patients and investigators who took part in the COMBI-I study and claimed that their collaboration has raised understanding of spartalizumab and its potential role in future cancer treatments at Novartis.

Reportedly, COMBI-I study investigators and people at Novartis will continue to analyze the data to gain more information from the results, which are likely to be taken forward to a presentation at a future medical meeting.

Novartis continues to search for more uses of immunotherapy in cancer treatment, along with the latest ongoing development of spartalizumab, across a plethora of tumors.  

Source credits-

https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-evaluating-investigational-spartalizumab-pdr001-combination-tafinlar-mekinist-advanced-melanoma

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Universal Music Group leaps to USD 55 billion in stock market debut

Universal Music Group leaps to USD 55 billion in stock market debut

By Nikita Chaurasia

Universal Music Group's stock market debut marked Europe the largest listing this year, with shares surging over a third as investors wager on the potential of music streaming in the long run. The world's largest music label, which represent...

Microsoft offering internships to boost technology skills in Indians

Microsoft offering internships to boost technology skills in Indians

By Nikita Chaurasia

Microsoft Corporation has reportedly launched the new Future Ready Talent internship program to teach technology skills to the Indian youth to make them job-ready. The program is free of cost and can be available for students who have graduated in 2...

PepsiCo to cut plastic use, launch plant-based snacks in green push

PepsiCo to cut plastic use, launch plant-based snacks in green push

By Nikita Chaurasia

As the necessity for actions that tackle climate change intensifies, PepsiCo has announced that it will reduce the use of virgin plastic and expand its business of SodaStream carbonated water to more markets, however, some environmental groups want t...

Google fined USD 177 Mn by South Korea over anti-competitive practices

Google fined USD 177 Mn by South Korea over anti-competitive practices

By Nikita Chaurasia

The fine is considered to be the ninth-biggest by the regulator to date. It was announced when South Korea’s Telecommunications Business Act, popularly known as “anti-Google law” came into effect.  South Korea’s Kore...

England to become the first country to require EV chargers in new homes

England to become the first country to require EV chargers in new homes

By Nikita Chaurasia

Even the commercial establishments will be required to include EV chargers. The news echoes on U.K.’s efforts to achieve net-zero greenhouse gas emissions by 2050. The British government is expected to introduce a new law in 2021 which wi...